McGill researchers have identified two proteins that work together to drive neuroinflammation in acute conditions such as microbial or autoimmune encephalitis, and in chronic conditions such as multiple sclerosis.
As part of a new venture in the Moitessier research group, recent Ph.D graduate, Josh Pottel, has delved into developing software to guide protein engineering. Computers can be used to simulate the shape and function of a protein or enzyme, but need the correct tools to be able to create accurate models. An initial platform for generating and applying new side-chain (rotamer) libraries has shown promise as the foundation for a biocatalysis prediction software.
The brain is a privileged organ in the body. So vital to life, the brain is protected from alterations elsewhere in the body by a highly regulated gateway known as the blood-brain barrier, which allows only selected molecules to pass through.
Research opens door to new drug therapies for Parkinson’s disease
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.